scholarly journals Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma

Cancer ◽  
2009 ◽  
pp. NA-NA ◽  
Author(s):  
Eric Jonasch ◽  
Paul Corn ◽  
Lance C. Pagliaro ◽  
Carla L. Warneke ◽  
Marcella M. Johnson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Interferon Alfa ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Randomized Phase 2

scholarly journals EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma

2015 ◽  
Vol 26 (6) ◽  
pp. 1118-1123 ◽  
Author(s):  
I.D. Davis ◽  
A. Long ◽  
S. Yip ◽  
D. Espinoza ◽  
J.F. Thompson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Phase 2 Trial ◽  
Line Therapy

scholarly journals Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800)

2015 ◽  
Vol 13 (6) ◽  
pp. 531-539.e1 ◽  
Author(s):  
Michael A. Carducci ◽  
Judith Manola ◽  
Suresh G. Nair ◽  
Glenn Liu ◽  
Steven Rousey ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cancer Research ◽  
Cell Carcinoma ◽  
Research Group ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 2 ◽  
Phase 2 Trial
Sign in / Sign up

Export Citation Format

Share Document